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Abstract
Background: Safety and efficacy of bioresorbable vascular scaffolds (BRS) and the role of 
postdilatation on outcome in acute coronary syndrome (ACS) patients compared with those 
of everolimus-eluting stents (EES) remain unknown. The aim of the study is to compare the 
safety and efficacy of BRS with EES in ACS and to investigate the role of BRS postdilatation.
Methods: Consecutive ACS patients undergoing BRS implantation in 8 centers were com-
pared with those with EES before and after propensity score matching. Major adverse cardiac 
event (MACE), myocardial infarction, and target lesion revascularization (TLR) were the 
primary endpoint. Sensitivity analysis was performed according to postdilatation after BRS 
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implantation. We enrolled 303 BRS and 748 EES patients; 215 from each group were com-
pared after matching, and 117 (55.2%) BRS patients were treated with postdilatation. 
Results: After a median follow-up of 24.0 months, MACE rates were higher in BRS patients 
than in EES patients (9.3% vs. 4.7%, p < 0.001), mainly driven by TLR (6.1% vs. 1.9%, 
p < 0.001). Stent thrombosis increased in the BRS group (2.8% vs. 0.9%, p = 0.01). How-
ever, after sensitivity analysis, MACE rates in BRS patients with postdilatation were signifi-
cantly lower than in those without, comparable to EES patients (6.0% vs. 12.6% vs. 4.7%, 
p < 0.001). The same trend was observed for TLR (3.4% vs. 8.4% vs. 1.9%, p < 0.001). Stent 
thrombosis rates were higher in both the BRS groups than in EES patients (2.6% vs. 3.2% vs. 
0.9%, p = 0.045). 
Conclusions: Postdilatation appears effective when using BRS in ACS patients. MACE rates 
are comparable to those of EES, although scaffold thrombosis is not negligible. Randomized 
prospective studies are required for further investigation. (Cardiol J 2016; 23, 4: 374–383)
Key words: angina pectoris, myocardial infarction, coronary restenosis,  
thrombosis, cardiac death
Introduction
Patients with acute coronary syndrome (ACS) 
represent a peculiar case for interventional cardiol-
ogy because of the high risk of thrombosis and 
challenging lesions in unstable presentation [1, 2]. 
Second generation drug-eluting stents (DES) such 
as everolimus-eluting stents (EES) and zotaroli-
mus-eluting stents are the treatment of choice 
for ACS patients because of their superiority in 
terms of reducing subsequent revascularizations 
[3]. The most critical limit of DES as metal stent 
is the permanent caging of the coronary vessel, 
which increases the risk of neointima proliferation 
and very late stent thrombosis (ST) and may ren-
der surgical revascularization no longer feasible 
for patients with severe diffuse disease [4–7]. 
Recently, bioresorbable vascular scaffolds (BRS) 
were introduced, which provide temporary ves-
sel scaffolding with drug delivery capacity but do 
not carry the limitations of a permanent metallic 
stent in the long term [8, 9]. Prospective studies 
demonstrated BRS safety and efficacy on selected 
patients [10–12], but some studies have reported 
increased ST rates [13–19]. However, data on 
a large sample of ACS patients are still lacking [15, 
17, 20–24], and only few studies have evaluated 
the impact of lesion preparation and postdilatation 
of BRS [25–27]. The aim of the present study 
was to compare the safety and efficacy of BRS 
with those of EES in patients with ACS and to 
investigate the potential role of BRS postdilata-
tion on outcome.
Methods
All consecutive BRS patients in 8 high-volume 
centers from Switzerland, Italy, and Germany (Sup-
plementary Methods: see journal website) were 
enrolled and compared with consecutive patients 
from the Zurich ACS registry treated with EES at 
the Universität Spital Zurich, Switzerland. Patients 
admitted with a diagnosis of ACS according to Eu-
ropean Society of Cardiology guidelines (unstable 
angina, non-ST segment elevation myocardial 
infarction, and ST segment elevation myocardial 
infarction [STEMI]) [28]. Baseline characteristics 
(age, gender, cardiovascular risk factors, and clini-
cal presentation) and procedural features (target 
vessel; site and type of lesion [29]; and number, 
length, and diameter of stents) were collected. 
For BRS patients, the number and atmospheres 
of pre- and postdilatation and use of intravascular 
ultrasound (IVUS) or optical coherence tomogra-
phy (OCT) were also recorded. Ethics approval was 
obtained from the Institutional Review Committees 
in the all institutions. All studies been performed 
in accordance with the ethical standards laid down 
in the 1964 Declaration of Helsinki and its later 
amendments. As this was retrospective study, no 
informed consent was required.
All percutaneous coronary interventions (PCI) 
were performed according to current standards, 
with mandatory predilatation and scaffold im-
plantation at pressure below the indicated burst 
pressure. Specific treatment strategies including 
postdilatation were performed at physician’s dis-
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cretion. Unless patients were already on chronic 
aspirin therapy, a loading dose of 250–500 mg 
aspirin was administered before PCI, followed 
by 75–100 mg once daily (od) dose indefinitely 
thereafter. Similarly, unless patients were al-
ready on chronic maintenance therapy, a loading 
dose of clopidogrel (600 mg), prasugrel (60 mg), 
or ticagrelor (180 mg) was administered be-
fore or immediately after PCI, followed by 
a maintenance dose of clopidogrel (75 mg od), 
prasugrel (10 mg od), or ticagrelor (90 mg twice 
daily) for 12 months. The use of glycoprotein 
IIb/IIIa inhibitors was at the physician’s discretion.
Patients either received treatment with BRS 
(Absorb, Abbott Vascular, Santa Clara, CA, USA) 
or treatment with EES (Xience, Abbott Vascular, 
Santa Clara, CA, USA). Postdilatation data recorded 
included the kind of balloon, size (mm), atmos-
pheres of postdilatation, and final size reached. 
Postdilatation was deemed effective if a noncompli-
ant balloon was inflated to no more than 0.5 mm 
larger than BRS.
Major adverse cardiac event (MACE), a com-
posite of death from any cause, myocardial infarc-
tion (MI), and clinically driven target lesion re-
vascularization (TLR), was the primary end point, 
whereas all components and clinically driven target 
vessel revascularization (TVR) as well as ST were 
secondary end points. Specifically, Academic Re-
search Consortium [30] differentiated ST as early 
(0–30 days), late (31–365 days), or very late (> 365 
days). Definite ST was defined as angiographically 
or pathologically proven ST, whereas probable ST 
was defined as any unexplained death within the 
first 30 days after stenting or any MI, irrespective 
of time after procedure, related to documented 
acute ischemia in the territory of the implanted 
stent, without angiographic confirmation of ST, and 
in the absence of any other obvious cause.
Statistical analysis
Continuous variables are presented as mean 
± standard deviation or median with interquartile 
range, and categorical variables are presented 
as frequency (%). Categorical variables were 
compared using Fisher’s exact test. Parametric 
distribution of continuous variables was tested 
graphically and with Hosmer-Lemeshow test, 
and appropriate analyses were used in accordance 
with the results. For propensity score, first logistic 
regression analysis was performed for all baseline 
features that differed between BRS and EES groups 
and for age, gender, diabetes mellitus, presence of 
type C lesions, and admission diagnosis. Match-
ing was computed after division into quintiles and 
methods of nearest neighbor on the estimated 
propensity score [26]. Calibration was tested us-
ing Hosmer-Lemeshow test, and accuracy was 
assessed with area under the curve. Standardized 
differences were evaluated before and after match-
ing to evaluate the performance of the model. The 
cumulative incidences of the primary endpoint and 
the secondary endpoints were calculated using 
the Kaplan-Meier method with median follow-up 
analysis, and differences among the groups were 
analyzed using a stratified log-rank test. All statisti-
cal analyses were performed using SPSS 21, and 
differences were considered significant at a = 0.05. 
Plots were created using Graphpad Prism 6.
Results
In total, 303 BRS and 748 EES patients were 
enrolled (Fig. 1). 
Clinical presentation significantly differed 
between the groups (STEMI: 39.6% vs. 54.8%, 
p < 0.001) (Table 1). 
At baseline, BRS patients were more likely 
to suffer from hypertension (60.3% vs. 52.6%, 
p = 0.03). Coronary angiography showed that 
left anterior descending coronary artery was the 
most frequently treated vessel (54.6% vs. 50.4%), 
followed by the right coronary artery (27.0% vs. 
27.2%, p = 0.32). Type C lesions were present in 
41.9% and 38.3% (p = 0.40) of the patients with 
a mean stent diameter of 3.1 ± 0.4 mm vs. 3.0 ± 
± 0.4 mm (p < 0.001) and a mean length of 20.6 ± 
± 5.2 mm vs. 20.0 ± 5.4 mm (p = 0.07), respectively 
(Table 1). Postdilatation was performed in 49.2% of 
BRS patients (n = 148) with noncompliant balloons 
and a mean pressure of 20 ± 6 atm. Intracoronary 
imaging was performed on 20.0% (IVUS) and 3.0% 
(OCT) of BRS patients. After a median follow-up 
of 24.0 (14.3–24.0) months, Kaplan-Meier curves 
showed that the rates of MACE were significantly 
higher in BRS patients (8.9% vs. 5.9%, p < 0.001), 
primarily due to an increased risk of TLR (5.3% vs. 
1.6%, p < 0.001) and MI (4.3% vs. 3.1%, p = 0.02). 
Death rate was not different between the groups 
(2.9% vs. 1.7%, p = 0.45). ST was higher in the 
BRS group (2.3% vs. 1.2%, p = 0.03) (Fig. 2) (Sup-
pl. Table 1 and Suppl. Fig. 1A: see journal website). 
After propensity score matching, 215 BRS 
and EES patients, each, with similar clinical pres-
entation, baseline risk factors, and angiographic 
features were selected (Fig. 1, Table 2). 
Thus, the results of the initial study on 
the overall population were confirmed. In fact, 
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at 2 years of follow-up, Kaplan-Meier curves dem-
onstrated higher rates of MACE in BRS patients 
(9.3% vs. 4.7%, p < 0.001). Furthermore, BRS pa-
tients were significantly more likely to experience 
TLR (6.1% vs. 1.9%, p < 0.001) and TVR (8.9% 
vs. 2.8%, p < 0.001) than their EES counterparts. 
Death or MI rates were comparable between the 
groups (2.3% vs. 1.9%, p = 0.91; 3.7% vs. 2.8%, 
Table 1. Baseline characteristics of the total study cohort (prematching).
BRS EES P
Females 68/303 (22.4%) 140/748 (18.7%) 0.17
Age [years] 60.7 ± 12.4 62.2 ± 11.6 0.09
Hypertension 182/302 (60.3%) 392/745 (52.6%) 0.03
Diabetes 37/302 (12.3%) 116/748 (15.5%) 0.21
Hyperlipidemia 125/302 (41.4%) 299/745 (40.1%) 0.73
Smoke 144/302 (47.7%) 325/745 (43.6%) 0.24
Ejection fraction [%] 53.2 ± 9.6 53.6 ± 11.3 0.70
STEMI 120/303 (39.6%) 410/748 (54.8%) < 0.001
Use of GP III 6/85 (7.6%) 191/746 (25.6%) < 0.001
Target vessel: 0.32
LM 1/359 (0.3%) 7/699 (1.0%)
LAD 196/359 (54.6%) 352/699 (50.4%)
LCX 62/359 (17.3%) 136/699 (19.5%)
RCA 97/359 (27.0%) 190/699 (27.2%)
Graft 3/359 (0.8%) 14/699 (2.0%)
Type C lesion 134/320 (41.9%) 105/274 (38.3%) 0.40
Stent length [mm] 20.6 ± 5.2 20.0 ± 5.4 0.07
Stent diameter [mm] 3.1 ± 0.4 3.0 ± 0.4 < 0.001
BRS — bioresorbable vascular scaffold; EES — everolimus-eluting stent; GP — glycoprotein; LAD — left anterior descending; LCX — left cir-
cumflex artery; LM — left main; RCA — right coronary artery; STEMI — ST segment elevation myocardial infarction; P-value: unpaired t-test 
or Fisher’s exact test
Figure 1. Flow diagram of the study; ACS — acute coronary syndrome; BRS — bioresorbable vascular scaffold; 
EES — everolimus-eluting stent.
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p = 0.18; respectively). ST was also higher in the 
BRS group (2.8% vs. 0.9%, p = 0.01) (Fig. 3) (Suppl. 
Table 2 and Suppl. Fig. 2A: see journal website).
In total, 148 (49.2%) of the BRS patients 
were treated with postdilatation before propensity 
score matching and 117 (55.2%) were treated after 
Table 2. Baseline characteristics of the matched study cohort (postmatching).
BRS EES P
Females 44/214 (20.6%) 42/215 (19.5%) 0.81
Age [years] 59.7 ± 13.0 61.5 ± 11.9 0.18
Hypertension 120/214 (56.1%) 117/215 (54.4%) 0.77
Diabetes 30/214 (14.0%) 36/215 (16.7%) 0.50
Hyperlipidemia 88/214 (41.1%) 92/215 (42.8%) 0.77
Smoke 110/214 (51.4%) 89/215 (41.4%) 0.04
Ejection fraction [%] 51.9 ± 9.5 53.7 ± 11.7 0.13
STEMI 105/214 (49.1%) 97/215 (45.1%) 0.44
Use of GP III 3/46 (6.5%) 70/213 (32.9%) < 0.001
Target vessel: 0.001
LM 1/249 (0.4%) 5/212 (2.4%)
LAD 141/249 (56.6%) 96/212 (45.3%)
LCX 40/249 (16.1%) 38/212 (17.9%)
RCA 67/249 (26.9%) 65/212 (30.7%)
Graft 0/249 (0.0%) 8/212 (3.8%)
Type C lesion 111/232 (47.8%) 100/240 (41.7%) 0.20
Stent length [mm] 20.8 ± 5.2 19.7 ± 5.1 0.01
Stent diameter [mm] 3.1 ± 0.4 3.0 ± 0.4 0.004
BRS — bioresorbable vascular scaffold; EES — everolimus-eluting stent; GP — glycoprotein; LAD — left anterior descending; LCX — left cir-
cumflex artery; LM — left main; RCA — right coronary artery; STEMI — ST segment elevation myocardial infarction; P-value: unpaired t-test 
or Fisher’s exact test
Figure 2. Outcomes at median follow-up for the total study cohort. Comparison between bioresorbable vascular scaf-
folds (BRS) and everolimus-eluting stents (EES) before and after sensitivity analysis for postdilatation (PD); MACE 
— major adverse cardiac events (composite of death, myocardial infarction [MI], and target lesion revascularization 
[TLR]); ST — stent thrombosis; TVR — target vessel revascularization; w/o — without.
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matching (Fig. 1) (Suppl. Table 3 and Suppl. Table 4: 
see journal website). Of these 148 patients, 95% 
were considered as effectively postdilatated using 
a noncompliant balloon inflated to no more than 
0.5 mm larger than BRS. In the total study cohort, 
rates of MACE in BRS patients with postdilata-
tion were significantly lower than those without 
postdilatation and were comparable to those ob-
served in the EES group (4.7% vs. 12.4% vs. 5.9%, 
p < 0.001, in BRS with postdilatation, BRS without 
postdilatation, and EES [the same order through-
out]) (Figs. 2, 4) (Suppl. Table 5 and Suppl. Fig. 1B: 
see journal website). 
These differences were mainly driven by 
lower rates of TLR (2.7% vs. 7.2% vs. 1.6%, 
p < 0.001). On the other hand, ST rates were only 
slightly lower in the BRS group with postdilatation 
but were higher in both the BRS groups than in 
EES patients (2.0% vs. 2.6% vs. 1.2%, p = 0.09), 
although this difference was not significant.
After propensity score matching, Kaplan-
Meier curves confirmed results from the total 
cohort. The rates of MACE in the BRS patients 
with postdilatation were again comparable to those 
observed in the EES group, with both subgroups 
showing significantly lesser MACE than BRS pa-
tients without postdilatation (6.0% vs. 12.6% vs. 
4.7%, p < 0.001) (Figs. 3, 5) (Suppl. Table 6 and 
Suppl. Fig. 2B: see journal website). 
These differences were also mainly driven 
by lower rates of TLR (3.4% vs. 8.4% vs. 1.9%, 
p < 0.001). Finally, ST rates were only slightly 
lower in the BRS group with postdilatation but still 
remained higher in both the BRS groups than in 
EES patients (2.6% vs. 3.2% vs. 0.9%, p = 0.045).
Discussion
The present study provides new insights on 
actual BRS implantation in ACS patients, demon-
strating the crucial role of effective postdilatation. 
We showed that in long-term follow-up, a) patients 
with effective postdilatation had similar rates of 
MACE and TLR compared with EES patients, 
b) MACE in BRS patients without postdilatation 
was mainly driven by TLR and was higher than 
that in EES patients, and c) scaffold thrombosis 
was not negligible. 
In our study, postdilatation was performed 
using high-pressure noncompliant balloons in 49% 
of the patients and these data suggest that opti-
mal postdilatation improves the outcome of BRS 
implantation, even in the population of ACS with 
relatively complicated lesions. Postdilatation using 
a high-pressure balloon is known as the standard 
deployment technique of contemporary metallic 
stents because the risk of TVR and ST is related to 
the final stent dimensions as guided by IVUS [31, 
32]. Metallic stents have a stable structure that is 
able to provide reliable and compliant expansion of 
the struts without the risk of disruption; however, 
BRS with polymeric materials has raised concerns 
Figure 3. Outcomes at median follow-up for the matched study cohort. Comparison between bioresorbable vascular 
scaffolds (BRS) and everolimus-eluting stents (EES) before and after sensitivity analysis for postdilatation (PD); MACE 
— major adverse cardiac events (composite of death, myocardial infarction [MI], and target lesion revascularization 
[TLR]); ST — stent thrombosis; TVR — target vessel revascularization; w/o — without.
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regarding over-expansion, disruption, and the 
effect of postdilatation following its implantation 
[27, 33]. For the full expansion of BRS, a recent 
practical review has recommended that postdilata-
tion should use short noncompliant balloons of no 
more than 0.5 mm larger than the nominal scaffold 
size, although clear and supporting data are not 
available [25]. The maximum recommended scaf-
fold expansion is no more than 0.5 mm larger than 
the nominal scaffold size, which should be followed 
during the procedure to prevent strut fracture 
[25]. In the present study, the mean implantation 
length was longer in BRS patients as compared to 
EES patients after matching. Type C lesion was 
more frequently observed in BRS patients than 
EES patients, although the difference was not 
significant. In addition, the use of glycoprotein 
IIb/IIIa inhibitors was more frequent in EES pa-
tients than BRS patients. Indeed, these differ-
ences were in favor of EES patients. Moreover, 
BRS patients with postdilatation had longer scaf-
fold length, more type C lesions and less use of 
glycoprotein IIb/IIIa than BRS patients without 
postdilatation. Nevertheless, BRS patients with 
postdilatation had favorable results compared to 
BRS patients without postdilatation.
Notwithstanding, the rate of scaffold throm-
bosis was not negligible. In fact, concerns about 
ST of BRS have recently been raised [14, 15]. 
A retrospective study of not only ACS but also 
stable angina patients showed stent thrombosis 
can be reduced when guideline-based implantation 
protocol with appropriate BRS size and pre-and 
postdilatation was employed [13]. However, in 
ACS patients of the present study, ST rates still 
remained higher in both the BRS groups than in 
EES group. ST occurred more frequently in the 
subgroup of patients without postdilatation. ST 
represents an important issue in the ACS setting as 
it is potentially triggered by enhanced aggregation 
Figure 4. Kaplan-Meier estimates of the outcomes in the total study cohort. Comparison with sensitivity analysis for 
postdilatation (PD); BRS — bioresorbable vascular scaffold; EES — everolimus-eluting stent; MACE — major adverse 
cardiac events (composite of death, myocardial infarction [MI], and target lesion revascularization [TLR]); w/o — with-
out; A. MACE; B. Death; C. MI; D. TLR.
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of platelets [34]. BRS represents a potential risk for 
scaffold thrombosis because of the relatively thick 
struts and limited expansion. A first randomized 
trial comparing BRS and EES in STEMI patients 
with simple lesion showed complete arterial heal-
ing with low device-oriented events at 6 months; 
however, 1.1% scaffolds thrombosis was reported 
in early phase [24]. The authors presumed that it 
was due to an inappropriate matching of the scaf-
fold to the vessel size. Intravascular imaging was 
used in limited cases in the present study. The 
imaging techniques especially OCT have higher 
resolution, so that scaffold integrity, apposition 
to the underlying wall, presence of thrombus and 
changes in strut characteristics during the inter-
vention and on follow-up should be studied in the 
further investigation.
Our results differ from those of previous large 
randomized trials, possibly because of different 
patient presentation and different angiographic le-
sions. In fact, patients in the trials only presented 
for unstable angina in 9.8–24% of the cases and 
the rates of type C lesions were 2–20% (compared 
with 41.9% in our complete ACS cohort) [10–12]. 
The other previous reports on BRS implantation 
in patients with higher risk lesions showed vary-
ing results. On one hand, in the GHOST registry, 
a large European real-world study of BRS, the 
prevalence of ACS was 47.4%, including 16.1% 
STEMI. Lesion types B2 and C were 23.6% and 
27.6%, respectively. This study showed the annual-
ized rates for cardiac death, target vessel MI, TLR, 
TVR, and target vessel failure to be 1.6%, 3.6%, 
7.0%, 10.2%, and 11.9%, respectively [19]. On the 
other hand, some recent reports have shown that 
BRS may be safely implanted for thrombotic lesions 
in ACS and STEMI [15–17, 22, 23]. Brugaletta et al. 
[15] used propensity score matching to show that 
1-year results between BRS and EES patients or 
bare-metal stents (BMS) did not significantly differ. 
Figure 5. Kaplan-Meier estimates of the outcomes in the matched study cohort. Comparison with sensitivity analysis 
for postdilatation (PD); BRS — bioresorbable vascular scaffold; EES — everolimus-eluting stent; MACE — major 
adverse cardiac events (composite of death, myocardial infarction [MI], and target lesion revascularization [TLR]); 
w/o — without; A. MACE; B. Death; C. MI; D. TLR.
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In that study, device-oriented endpoints including 
cardiac death, target vessel MI, and TLR in BRS 
were similar to those of EES or BMS patients 
(4.1% and 4.1% [p = 0.99] or 5.9% [p = 0.31], 
respectively) although scaffolds thrombosis was 
not negligible. Other recent studies evaluating 
BRS show different rates of target lesion failure 
and ST rate. If evaluated closely, these studies 
show differences in the study population (ACS or 
not), in the lesion severity and particularly in the 
postdilatation rates. In fact, the use of postdilata-
tion in BRS studies fluctuated from 14% in some 
series to more than 60% and even up to 90% in 
other studies [10, 19, 35].
Limitations of the study
The present study has some limitations. First, 
these data are retrospectively analyzed and derived 
from nonrandomized evidence, although propensity 
score matching showed good accuracy (area under 
the curve of 0.81 [0.76–0.85] and calibration (non-
significant Hosmer-Lemeshow test). Second, the 
data concerning dual antiplatelet regimen were not 
available and the ratio of dual antiplatelet therapy 
discontinuation was unknown. Third, data at longer 
follow-up time-points are needed to correctly 
evaluate performance after the disappearance of 
the scaffolds. 
Conclusions
Postdilatation appears to be effective when us-
ing BRS in patients presenting with ACS and leads 
to MACE rates that are comparable to those of 
EES, although scaffold thrombosis is not negligible. 
Randomized prospective studies are required to 
further investigate BRS safety and efficacy in ACS. 
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